Esculin protects against methionine choline-deficient diet-induced non-alcoholic steatohepatitis by regulating the Sirt1/NF-κB p65 pathway

References

• Biljali S, Hadjimitova VA, Topashka-Ancheva MN, Momekova DB, Traykov TT, Karaivanova MH. 2012. Antioxidant and antiradical properties of esculin, and its effect in a model of epirubicin-induced bone marrow toxicity. Folia Med. 54(3):42–49.
   Google Scholar
• De Lorenzo S, Tovoli F, Mazzotta A, Vasuri F, Edeline J, Malvi D, Boudjema K, Renzulli M, Jeddou H, D'Errico A, et al. 2020. Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role. Cancers. 12(11):3182.
   PubMed Web of Science ®Google Scholar
• Gasparini C, Feldmann M. 2012. NF-κB as a target for modulating inflammatory responses. Curr Pharm Des. 18(35):5735–5745.
   PubMed Web of Science ®Google Scholar
• Gluchowski NL, Becuwe M, Walther TC, Farese RJ. 2017. Lipid droplets and liver disease: from basic biology to clinical implications. Nat Rev Gastroenterol Hepatol. 14(6):343–355.
   PubMed Web of Science ®Google Scholar
• Gonzalez A, Huerta-Salgado C, Orozco-Aguilar J, Aguirre F, Tacchi F, Simon F, Cabello-Verrugio C. 2020. Role of oxidative stress in hepatic and extrahepatic dysfunctions during nonalcoholic fatty liver disease (NAFLD). Oxid Med Cell Longev. 2020:1617805.
   PubMed Web of Science ®Google Scholar
• Huang B, Yang XD, Lamb A, Chen LF. 2010. Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal. 22(9):1282–1290.
   PubMed Web of Science ®Google Scholar
• Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. 2020. Animal models of fibrosis in nonalcoholic steatohepatitis: do they reflect human disease? Adv Nutr. 11(6):1696–1711.
   PubMed Web of Science ®Google Scholar
• Isaza SC, Del PE, Dominguez-Alcon L, Elbouayadi L, Gonzalez-Rodriguez A, Garcia-Monzon C. 2020. Hypoxia and non-alcoholic fatty liver disease. Front Med. 7:578001.
   Google Scholar
• Jiang N, Lv J, Wang H, Huang H, Wang Q, Lu C, Zeng G, Liu XM. 2020. Ginsenoside Rg1 ameliorates chronic social defeat stress-induced depressive-like behaviors and hippocampal neuroinflammation. Life Sci. 252:117669.
   PubMed Web of Science ®Google Scholar
• Jimi E, Fei H, Nakatomi C. 2019. NF-kappaB signaling regulates physiological and pathological chondrogenesis. IJMS. 20(24):6275.
   Google Scholar
• Kang KS, Lee W, Jung Y, Lee JH, Lee S, Eom DW, Jeon Y, Yoo HH, Jin MJ, Song KI, et al. 2014. Protective effect of esculin on streptozotocin-induced diabetic renal damage in mice. J Agric Food Chem. 62(9):2069–2076.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lim Y, Park JB, Kwak JH, Kim KJ, Kim JH, Song H, Cho JY, Hwang DY, Kim KS, et al. 2017. Erratum: comparative study of fatty liver induced by methionine and choline-deficiency in C57BL/6N mice originating from three different sources. Lab Anim Res. 33(4):318.
   PubMedGoogle Scholar
• Kragh PS, Bilkei-Gorzo O, Govaere O, Hartlova A. 2020. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD). Scand J Immunol. 92(5):e12971.
   PubMed Web of Science ®Google Scholar
• Kuchay MS, Choudhary NS, Mishra SK. 2020. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 14(6):1875–1887.
   PubMed Web of Science ®Google Scholar
• Kumar DP, Caffrey R, Marioneaux J, Santhekadur PK, Bhat M, Alonso C, Koduru SV, Philip B, Jain MR, Giri SR, et al. 2020. The PPAR α/γ agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease. Sci Rep. 10(1):9330.
   PubMed Web of Science ®Google Scholar
• Liu A, Shen Y, Du Y, Chen J, Pei F, Fu W, Qiao J. 2018. Esculin prevents lipopolysaccharide/d-galactosamine-induced acute liver injury in mice. Microb Pathog. 125:418–422.
   PubMed Web of Science ®Google Scholar
• Meng Y, Liu Y, Fang N, Guo Y. 2019. Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat. Pharm Biol. 57(1):98–104.
   PubMed Web of Science ®Google Scholar
• Mitchell S, Vargas J, Hoffmann A. 2016. Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med. 8(3):227–241.
   PubMed Web of Science ®Google Scholar
• Mokdad Bzeouich I, Mustapha N, Maatouk M, Ghedira K, Ghoul M, Chekir-Ghedira L. 2016. Genotoxic and anti-genotoxic effects of esculin and its oligomer fractions against mitomycin C-induced DNA damages in mice. Regul Toxicol Pharmacol. 82:48–52.
   PubMed Web of Science ®Google Scholar
• Mokdad-Bzeouich I, Kovacic H, Ghedira K, Chebil L, Ghoul M, Chekir-Ghedira L, Luis J. 2016. Esculin and its oligomer fractions inhibit adhesion and migration of U87 glioblastoma cells and in vitro angiogenesis. Tumour Biol. 37(3):3657–3664.
   PubMedGoogle Scholar
• Mokdad-Bzeouich I, Mustapha N, Chaabane F, Ghedira Z, Ghedira K, Ghoul M, Chebil L, Chekir-Ghedira L. 2015. Oligomerization of esculin improves its antibacterial activity and modulates antibiotic resistance. J Antibiot. 68(3):148–152.
   PubMed Web of Science ®Google Scholar
• Niu X, Wang Y, Li W, Zhang H, Wang X, Mu Q, He Z, Yao H. 2015. Esculin exhibited anti-inflammatory activities in vivo and regulated TNF-α and IL-6 production in LPS-stimulated mouse peritoneal macrophages in vitro through MAPK pathway. Int Immunopharmacol. 29(2):779–786.
   PubMed Web of Science ®Google Scholar
• Noureddin M, Muthiah MD, Sanyal AJ. 2020. Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab. 3:e105.
   Google Scholar
• Ou Q, Weng Y, Wang S, Zhao Y, Zhang F, Zhou J, Wu X. 2018. Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the NF-κB Pathway. Dig Dis Sci. 63(12):3398–3408.
   PubMed Web of Science ®Google Scholar
• Ozutsumi T, Namisaki T, Shimozato N, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Nakanishi K, Sato S, et al. 2020. Combined treatment with sodium-glucose cotransporter-2 inhibitor (Canagliflozin) and dipeptidyl peptidase-4 inhibitor (Teneligliptin) alleviates NASH progression in a non-diabetic rat model of steatohepatitis. IJMS. 21(6):2164.
   Google Scholar
• Pardo PS, Boriek AM. 2020. SIRT1 regulation in ageing and obesity. Mech Ageing Dev. 188:111249.
   PubMed Web of Science ®Google Scholar
• Revollo JR, Li X. 2013. The ways and means that fine tune Sirt1 activity. Trends Biochem Sci. 38(3):160–167.
   PubMed Web of Science ®Google Scholar
• Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL. 2020. The race to bash NASH: emerging targets and drug development in a complex liver disease. J Med Chem. 63(10):5031–5073.
   PubMed Web of Science ®Google Scholar
• Rong X, Wang B, Dunham MM, Hedde PN, Wong JS, Gratton E, Young SG, Ford DA, Tontonoz P. 2015. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. Elife. 4:e6557.
   Web of Science ®Google Scholar
• Tafani M, Pucci B, Russo A, Schito L, Pellegrini L, Perrone GA, Villanova L, Salvatori L, Ravenna L, Petrangeli E, et al. 2013. Modulators of HIF1α and NFkB in cancer treatment: is it a rational approach for controlling malignant progression? Front Pharmacol. 4(13):13.
   PubMedGoogle Scholar
• Tianzhu Z, Shumin W. 2015. Esculin inhibits the inflammation of LPS-induced acute lung injury in mice via regulation of TLR/NF-κB pathways. Inflammation. 38(4):1529–1536.
   PubMed Web of Science ®Google Scholar
• Wu B, Wang R, Li S, Wang Y, Song F, Gu Y, Yuan Y. 2019. Antifibrotic effects of fraxetin on carbon tetrachloride-induced liver fibrosis by targeting NF-κB/IκBα, MAPKs and Bcl-2/Bax pathways . Pharmacol Rep. 71(3):409–416.
   PubMed Web of Science ®Google Scholar
• Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. 2004. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J. 23(12):2369–2380.
   PubMed Web of Science ®Google Scholar